FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079698487> ?p ?o ?g. }

• W2079698487 abstract "Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, using a novel model-based approach, in patients with moderate-to-severe COPD.Double-blind, randomized, dose-finding trial with an eight-treatment, two-period, balanced incomplete block design. Patients (smoking history ≥10 pack-years, post-bronchodilator FEV1 ≥30% and <80% predicted, FEV1/FVC <0.7) were randomized to one of 16 independent sequences for 28 days. Primary endpoint: mean trough FEV1 at Day 28.385 patients (mean age 61.2 years; mean post-bronchodilator FEV1 53% predicted) were randomized; 88.6% completed. All OD and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12.5 μg OD) to 160 mL (glycopyrronium bromide 50 μg BID). Pharmacodynamic steady-state was reached by Day 7. There was a small separation (≤37 mL) between BID and OD dose-response curves for mean trough FEV1 at steady-state in favour of BID dosing. Over 24 hours, separation between OD and BID regimens was even smaller (FEV1 AUC0-24h maximum difference for equivalent daily dose regimens: 8 mL). Dose-response results for FEV1 at 12 hours, FEV1 AUC0-12h and FEV1 AUC0-4h at steady-state showed OD regimens provided greater improvement over placebo than BID regimens for total daily doses of 25 μg, 50 μg and 100 μg, while the reverse was true for OD versus BID regimens from 12-24 hours. The 12.5 μg BID dose produced a marginally higher improvement in trough FEV1 versus placebo than 50 μg OD, however, the response at 12 hours over placebo was suboptimal (74 mL). Glycopyrronium bromide was safe and well tolerated at all doses.Glycopyrronium bromide 50 μg OD provides significant bronchodilation over a 24 hour period, and in terms of FEV1 AUC0-24h is not significantly different than the same total daily dose administered BID. Importantly, OD dosing may confer better patient adherence. The results are consistent with previous glycopyrronium bromide studies and support once-daily dosing of glycopyrronium bromide 50 μg in patients with moderate-to-severe COPD.ClinicalTrials.gov: NCT01119950." @default.
• W2079698487 created "2016-06-24" @default.
• W2079698487 creator A5004305177 @default.
• W2079698487 creator A5009277081 @default.
• W2079698487 creator A5009331745 @default.
• W2079698487 creator A5010353100 @default.
• W2079698487 creator A5016621179 @default.
• W2079698487 creator A5042617883 @default.
• W2079698487 creator A5052626090 @default.
• W2079698487 date "2012-12-01" @default.
• W2079698487 modified "2023-10-07" @default.
• W2079698487 title "A novel model-based approach for dose determination of glycopyrronium bromide in COPD" @default.
• W2079698487 cites W1979168008 @default.
• W2079698487 cites W1984207232 @default.
• W2079698487 cites W1985644458 @default.
• W2079698487 cites W1988167365 @default.
• W2079698487 cites W1993643657 @default.
• W2079698487 cites W2002531019 @default.
• W2079698487 cites W2053538448 @default.
• W2079698487 cites W2064720111 @default.
• W2079698487 cites W2069984535 @default.
• W2079698487 cites W2080929522 @default.
• W2079698487 cites W2095049468 @default.
• W2079698487 cites W2095666112 @default.
• W2079698487 cites W2096849215 @default.
• W2079698487 cites W2105402505 @default.
• W2079698487 cites W2112628693 @default.
• W2079698487 cites W2119761903 @default.
• W2079698487 cites W2129929576 @default.
• W2079698487 cites W2132565543 @default.
• W2079698487 cites W2134091333 @default.
• W2079698487 cites W2138833643 @default.
• W2079698487 cites W2142724633 @default.
• W2079698487 cites W2151427273 @default.
• W2079698487 cites W2153810843 @default.
• W2079698487 cites W2160609432 @default.
• W2079698487 cites W2169573063 @default.
• W2079698487 cites W2171974515 @default.
• W2079698487 doi "https://doi.org/10.1186/1471-2466-12-74" @default.
• W2079698487 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3528484" @default.
• W2079698487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23217058" @default.
• W2079698487 hasPublicationYear "2012" @default.
• W2079698487 type Work @default.
• W2079698487 sameAs 2079698487 @default.
• W2079698487 citedByCount "26" @default.
• W2079698487 countsByYear W20796984872012 @default.
• W2079698487 countsByYear W20796984872013 @default.
• W2079698487 countsByYear W20796984872014 @default.
• W2079698487 countsByYear W20796984872015 @default.
• W2079698487 countsByYear W20796984872016 @default.
• W2079698487 countsByYear W20796984872017 @default.
• W2079698487 countsByYear W20796984872018 @default.
• W2079698487 countsByYear W20796984872020 @default.
• W2079698487 countsByYear W20796984872021 @default.
• W2079698487 countsByYear W20796984872022 @default.
• W2079698487 countsByYear W20796984872023 @default.
• W2079698487 crossrefType "journal-article" @default.
• W2079698487 hasAuthorship W2079698487A5004305177 @default.
• W2079698487 hasAuthorship W2079698487A5009277081 @default.
• W2079698487 hasAuthorship W2079698487A5009331745 @default.
• W2079698487 hasAuthorship W2079698487A5010353100 @default.
• W2079698487 hasAuthorship W2079698487A5016621179 @default.
• W2079698487 hasAuthorship W2079698487A5042617883 @default.
• W2079698487 hasAuthorship W2079698487A5052626090 @default.
• W2079698487 hasBestOaLocation W20796984871 @default.
• W2079698487 hasConcept C126322002 @default.
• W2079698487 hasConcept C142724271 @default.
• W2079698487 hasConcept C168563851 @default.
• W2079698487 hasConcept C170493617 @default.
• W2079698487 hasConcept C204787440 @default.
• W2079698487 hasConcept C27081682 @default.
• W2079698487 hasConcept C2776042228 @default.
• W2079698487 hasConcept C2776723954 @default.
• W2079698487 hasConcept C2776780178 @default.
• W2079698487 hasConcept C2776885963 @default.
• W2079698487 hasConcept C2777288759 @default.
• W2079698487 hasConcept C2781018748 @default.
• W2079698487 hasConcept C42219234 @default.
• W2079698487 hasConcept C71924100 @default.
• W2079698487 hasConceptScore W2079698487C126322002 @default.
• W2079698487 hasConceptScore W2079698487C142724271 @default.
• W2079698487 hasConceptScore W2079698487C168563851 @default.
• W2079698487 hasConceptScore W2079698487C170493617 @default.
• W2079698487 hasConceptScore W2079698487C204787440 @default.
• W2079698487 hasConceptScore W2079698487C27081682 @default.
• W2079698487 hasConceptScore W2079698487C2776042228 @default.
• W2079698487 hasConceptScore W2079698487C2776723954 @default.
• W2079698487 hasConceptScore W2079698487C2776780178 @default.
• W2079698487 hasConceptScore W2079698487C2776885963 @default.
• W2079698487 hasConceptScore W2079698487C2777288759 @default.
• W2079698487 hasConceptScore W2079698487C2781018748 @default.
• W2079698487 hasConceptScore W2079698487C42219234 @default.
• W2079698487 hasConceptScore W2079698487C71924100 @default.
• W2079698487 hasIssue "1" @default.
• W2079698487 hasLocation W20796984871 @default.
• W2079698487 hasLocation W20796984872 @default.
• W2079698487 hasLocation W20796984873 @default.
• W2079698487 hasLocation W20796984874 @default.
• W2079698487 hasOpenAccess W2079698487 @default.
• W2079698487 hasPrimaryLocation W20796984871 @default.

• next